Growth Metrics

Omeros (OMER) Non-Current Assets (2010 - 2026)

Omeros recorded quarterly Non-Current Assets of $105.8 million in Q1 2026, down 3.77% quarter-over-quarter from $110.0 million in Q4 2025, and down 23.86% year-over-year from $139.0 million in Q1 2025.

Omeros' Non-Current Assets history runs 17 years deep, the most recent figure standing at $105.8 million for Q1 2026.

  • In Q1 2026, Non-Current Assets fell 23.86% year-over-year to $105.8 million; the TTM figure through Mar 2026 stood at $460.6 million (down 21.09% YoY), while the FY2025 annual figure was $110.0 million, down 23.08% from the prior year.
  • Non-Current Assets came in at $105.8 million for Q1 2026 at Omeros, down from $110.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $169.0 million in Q3 2022 to a low of $105.8 million in Q1 2026.
  • A 5-year average of $142.0 million and a median of $143.1 million in 2023 frame the typical range for Non-Current Assets.
  • Across the five-year window, Non-Current Assets surged 449.14% in 2022 and decreased 23.86% in 2026, its largest moves.
  • Omeros' Non-Current Assets stood at $147.7 million in 2022, then climbed by 8.55% to $160.4 million in 2023, then slipped by 10.86% to $143.0 million in 2024, then slipped by 23.08% to $110.0 million in 2025, then fell by 3.77% to $105.8 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $105.8 million, $110.0 million, and $113.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 4.56 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 62,953.78
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 486.60 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 5.83 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 14.75 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 22.66 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 910.24 Mn
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn 105.82 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 105.82 Mn
Dec 31, 2025 109.97 Mn
Sep 30, 2025 113.90 Mn
Jun 30, 2025 130.92 Mn
Mar 31, 2025 138.98 Mn
Dec 31, 2024 142.96 Mn
Sep 30, 2024 148.41 Mn
Jun 30, 2024 153.38 Mn
Mar 31, 2024 156.53 Mn
Dec 31, 2023 160.37 Mn
Sep 30, 2023 141.73 Mn
Jun 30, 2023 138.86 Mn
Mar 31, 2023 143.10 Mn
Dec 31, 2022 147.73 Mn
Sep 30, 2022 169.01 Mn
Jun 30, 2022 152.92 Mn
Mar 31, 2022 159.04 Mn
Dec 31, 2021 171.31 Mn
Sep 30, 2021 32.08 Mn
Jun 30, 2021 32.99 Mn
Mar 31, 2021 28.96 Mn
Dec 31, 2020 29.76 Mn
Sep 30, 2020 31.09 Mn
Jun 30, 2020 31.76 Mn
Mar 31, 2020 32.60 Mn
Dec 31, 2019 33.22 Mn
Sep 30, 2019 27.46 Mn
Jun 30, 2019 23.82 Mn
Mar 31, 2019 24.38 Mn
Dec 31, 2018 6.07 Mn
Sep 30, 2018 9.61 Mn
Jun 30, 2018 9.85 Mn
Mar 31, 2018 10.35 Mn
Dec 31, 2017 7.96 Mn
Sep 30, 2017 7.62 Mn
Jun 30, 2017 7.26 Mn
Mar 31, 2017 7.05 Mn
Dec 31, 2016 7.02 Mn
Sep 30, 2016 12.11 Mn
Jun 30, 2016 12.00 Mn
Mar 31, 2016 11.65 Mn
Dec 31, 2015 11.85 Mn
Sep 30, 2015 1.95 Mn
Jun 30, 2015 1.96 Mn
Mar 31, 2015 1.85 Mn
Dec 31, 2014 1.79 Mn
Sep 30, 2014 1.93 Mn
Jun 30, 2014 2.03 Mn
Mar 31, 2014 1.94 Mn
Dec 31, 2013 1.72 Mn
Sep 30, 2013 1.74 Mn
Jun 30, 2013 1.79 Mn
Mar 31, 2013 1.88 Mn
Dec 31, 2012 1.88 Mn
Sep 30, 2012 1.32 Mn
Jun 30, 2012 1.55 Mn
Mar 31, 2012 1.39 Mn
Dec 31, 2011 1.03 Mn
Sep 30, 2011 1.15 Mn
Jun 30, 2011 1.28 Mn
Dec 31, 2010 1.95 Mn